Immupharma and Avion sign agreement for lupus drug Lupuzor

pharmafile | November 29, 2019 | News story | Medical Communications Diseases, Lupus, Lupuzor, avion 

Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and autophagy immunomodualtor for auto-immune disease systemic lupus erythematosus (SLE or lupus).

Under their agreement, the companies will co-develop the drug and allow the registration for marketing in the US, Europe and elsewhere. Avion will commercialise the drug exclusively for the US while Immupharma will retain all the rights for outside the US.

Dimitri Dimitriou, the Chief Executive Officer at ImmuPharma, said: “We are delighted to be entering into this partnership with Avion” adding that the company “look forward to a long and successful relationship with the Avion team”.

Art Deas, the CEO of Avion, also commented: “We believe that Lupuzor has a unique position within lupus that sets it apart from the competition and we are delighted to be extending our footprint. With approximately 1.5 million patients in the US suffering from lupus, there is a significant unmet need for a safe and effective drug for this debilitating disease that we believe Lupuzor can meet”.

The optimised Phase 3 clinal trial of the drug is scheduled to begin in 2020, over a period of one year, and is expected to include patients in the US and Europe. It will follow a trial design agreed by the two companies and the FDA.

Conor Kavanagh

Related Content

GSK building

GSK lupus treatment approved by European Commission

GSK’s Benlysta treatment, for patients with active lupus nephritis (LN) in addition to systemic lupus …

Expanded EU label for Benlyta now covers paediatric lupus patients

GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion …


Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome

Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment …

Latest content